Drugs / pNGVL4a-Sig/E7(detox)/HSP70
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03911076 | May 2019 → Jun 2022 | cervical adenosquamous carcinoma, cervical squamous intraepithelial neoplasia | PapiVax Biotech, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pNGVL4a-Sig/E7(detox)/HSP70 | “pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine)” NCT03911076 ↗ |
| Known as | pBI-1 | “pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine)” NCT03911076 ↗ |
| Modality | Vaccine | “pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine)” NCT03911076 ↗ |
| Route | Intramuscular | “dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen” NCT03911076 ↗ |